LncRNA Information | |||||
---|---|---|---|---|---|
ID | EL0630 | Name | CCND1 | Aliases | BCL1, D11S287E, PRAD1, U21B31 |
Species | Homo sapiens | Chromosome | 11 | Start site | 69641156 |
End site | 69654474 | Chain | plus | Exon NO. | 5 |
Assembly | GRCh38.p13 | Class | retained intron | NCBI accession | N/A |
Ensembl | N/A | Sequence | N/A | Peptide-related | N/A |
CircRNA | N/A | Exosomal | yes | Structure | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Drug/chemo/stress | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | ||
cervical cancer | qRT-PCR | cell line (CaSki) | up-regulated | N/A | Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. | 22487937 | |||
tumor | N/A | N/A | N/A | expression | Binding to TLS protein induces TLS allosteric change, allowing interaction with cyclin D1, inhibiting CBP and p300 activity, and silencing cyclin D1 gene expression. | 22996375 |
Function (not disease relevant) | ||||||||
---|---|---|---|---|---|---|---|---|
Drug/chemo/stress | Methods | Sample/condition | Expression pattern | Dysfunction type | Description | PMID | ||
exosomes secreted from cultured cells | up-regulated | expression | lincRNA-p21 and ncRNA-CCND1 were the main molecules; exosome levels of them best reflect the change of their cellular levels upon exposure of the cells to bleomycin-induced DNA damage. | 24798520 |